The top 9 overseas accounts in biopharma hold $133B in M&A firepower
Pictured (L-R): Stephen Ubl, CEO PhRMA; Ken Frazier, CEO Merck; Robert Hugin, Celgene chairman; Robert Bradway, CEO Amgen on January 31 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.